

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO ASSIGNMENT AGREEMENT WITH CALITHERA BIOSCIENCES, INC. TO ACQUIRE ALL OUTSTANDING RIGHTS OF ATG-037

Antengene Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company that a member of the Group has reached an assignment agreement (the “**Assignment Agreement**”) with Calithera Biosciences, Inc. (“**Calithera**”) to acquire all of the outstanding rights of ATG-037.

Antengene and Calithera entered into a worldwide exclusive license agreement to develop and commercialize ATG-037 in May, 2021. Under the terms of the license agreement, Calithera received an initial upfront payment and was eligible to receive payments on potential development, regulatory and sales milestones, and tiered royalties on sales of the licensed product within the range of single to low double-digits. Pursuant to the Assignment Agreement, Antengene is no longer obligated to pay any future milestones and royalty to Calithera, and Antengene will also acquire ownership of all patents and patent applications relating to ATG-037.

Accordingly, the board of directors of Antengene considers that the Assignment Agreement and the transactions contemplated thereunder are in the interests of Antengene and its shareholders as a whole.

As each of the applicable percentage ratios under Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in respect of the Assignment Agreement is under 5%, the transaction contemplated under the Assignment Agreement does not constitute a notifiable transaction of Antengene under Chapter 14 of the Listing Rules.

To the best knowledge and belief of the directors of Antengene, as of the date of this announcement, Calithera is independent of, and not connected with, Antengene and its connected persons (as defined in the the Listing Rules).

This is a voluntary announcement made by the Company. The Group cannot guarantee that ATG-037 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, January 4, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin and Mr. Donald A. Lung as executive directors; Dr. Kan Chen and Mr. Yilun Liu as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.

About ATG-037

ATG-037 is an orally bioavailable, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents. In preclinical studies, the compound has demonstrated the ability to overcome the “hook effect” that has been observed in some anti-CD73 antibodies. In addition, Good Laboratory Practices (“GLP”) toxicology studies indicate the compound potentially has a wide therapeutic window. Antengene has been approved to initiate the Phase I STAMINA-001 study of ATG-037 in patients with locally advanced or metastatic advanced solid tumors in Australia and China, and the patient enrollment for the study is currently ongoing.

About Antengene

Antengene Corporation Limited (SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders.”

Since 2017, Antengene has built a broad and expanding pipeline of 13 clinical and preclinical assets, of which 10 are global rights assets, and 3 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 27 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 9 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, Taiwan, South Korea, Singapore and Australia.

About Calithera

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially starve tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company’s Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange.